Celcuity Inc. (CELC) stock
Close on Nov 11, 2026Market cap $3.15BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $3.15B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -6.78%
Fundamentals
- Net income
- -$256.02M
- EPS, diluted
- -$4.71
- Free cash flow
- -$213.48M
- Book value per share
- -$1.34
- Diluted shares
- 55M
Trading
- Next earnings
- Mar 24, 2027 (estimated, after the close)
- Previous close
- $67.05
- Open
- $67.91
- Day's range
- $64.27 – $67.95
- Volume
- 696,796
- Average volume (20 days)
- 1,488,156
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 0.49
- 52-week range
- $53.54 – $151.02
- RSI (14 days)
- 43.0
- Volatility (1 year)
- 64.0%
- Relative volume
- 0.53×
- WACC
- 7.4%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CELC | S&P 500 | Difference | CELC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.3% | -2.4% | −2.9 pts | ||
| 3 months | -27.0% | -1.2% | −25.9 pts | ||
| Year to date | -35.5% | +12.3% | −47.8 pts | ||
| 1 year | -18.8% | +12.4% | −31.2 pts | ||
| 3 years | +497.2% | +78.8% | +418.4 pts | +81.4% | +21.4% |
| 5 years | +272.9% | +75.2% | +197.7 pts | +30.1% | +11.9% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Celcuity filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate UpdateResults
- Update
About Celcuity
Services-Medical Laboratories
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies to treat various solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor targeting class I PI3K isoforms and mTOR complexes (mTORC1 and mTORC2) to achieve comprehensive inhibition of the PAM signaling pathway. The company is evaluating this candidate in clinical studies primarily for patients with advanced breast cancer and metastatic castration-resistant prostate cancer who have experienced disease progression on prior standard therapies.
Company profile, executives and historyCelcuity stock: common questions
What is Celcuity's stock price?
CELC closed at $64.32 on Nov 11, 2026, down 4.07% on the day. Over the past 52 weeks it traded between $53.54 and $151.02.
What is Celcuity's market cap?
Celcuity was worth $3.15B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CELC's P/E ratio?
Celcuity lost money over the twelve months to Sep 30, 2026 (diluted EPS -$4.71), so it has no meaningful P/E ratio.
Does Celcuity pay a dividend?
No. Celcuity has not paid a cash dividend over the last twelve months.
When does Celcuity report earnings next?
Celcuity is expected to report Q4 FY2026 results on Mar 24, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CELC stock performed over the past year?
Including dividends, CELC returned -18.8% over the past year, against +12.4% for the S&P 500.
How many CELC shares are sold short?
10M shares were sold short at the latest FINRA report, 28.66% of the float, or 5.8 days of average trading volume.
Who are Celcuity's competitors?
Companies most similar to Celcuity by business, industry and size include BNR, PSNL, FLGT, CAI, FTRE.
See a number that looks wrong?